Trials / Completed
CompletedNCT02654028
Association Between Autologous Transfusion and Recurrence-free Survival in Patients With HCC After Resection
Association Between Autologous Transfusion and Recurrence-free Survival in Patients With Hepatocellular Carcinoma After Resection-a Prospective Non-randomized Controlled Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 618 (actual)
- Sponsor
- Guangxi Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This prospective non-randomized controlled trial aims to determine whether autotransfusion of red blood cells salvaged before liver resection is associated with the recurrence-free survival in patients with hepatocellular carcinoma.
Detailed description
Preoperative and intraoperative blood salvage autotransfusion is used in various surgical procedures. However, because of the risk of reinfusion of salvaged blood contaminated by tumor cells, the use of autotransfusion in hepatocellular carcinoma (HCC) patients undergoing liver resection is controversial. The critical points include whether tumor cells can be cleared by autotransfusion, whether autotransfusion increases the risk of recurrence or metastasis, and what are the indications for autotransfusion. Moreover, some other issues are still not addressed. For example, is it warranted to take the risk of tumor dissemination by using autotransfusion to avoid allogeneic blood transfusion? Do the remaining tumor cells after additional filtration by leukocyte depletion filters still possess potential tumorigenicity?
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Autotransfusion | These group of patients will receive autotransfusion before liver resection. |
| OTHER | Control group | These group of patients will not receive autotransfusion before liver resection. |
Timeline
- Start date
- 2019-01-05
- Primary completion
- 2021-12-30
- Completion
- 2021-12-30
- First posted
- 2016-01-13
- Last updated
- 2023-01-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02654028. Inclusion in this directory is not an endorsement.